Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation ...(on of the Company's use of these non-GAA...),Health

                          BOSTON SCIENTIFIC CORPORATION
       NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS
                                      (CONT.)
                                   (Unaudited)

                                   Three Months Ended     Nine Months Ended
                                   September 30, 2009    September 30, 2009
                                   ------------------    ------------------
                                  Previously     As     Previously     As
                                    Reported   Updated    Reported   Updated
                                  -----------  -------  -----------  -------
    Intangible asset impairment
     charges:
      Intangible asset impairment
       charges                                                  $10      $10
          Less: Income tax
           benefit (a)                                           (2)      (2)
                                                                 --       --
    Intangible asset impairment
     charges, net of tax                                         $8       $8
                                                                 ==       ==

    Acquisition-related charges:
      Purchased research and
       development                                              $17      $17
          Less: Income tax
           benefit (a)
                                                                ---      ---
    Acquisition-related charges,
     net of tax                                                 $17      $17
                                                                ===      ===

    Divestiture-related gains:
      Net gain on sale of
      investments (b)                                           $(3)     $(3)
          Less: Income tax
           expense (a)                                            1        
'/>"/>
SOURCE  Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death